Febuxostat

Generic Name
Febuxostat
Brand Names
Adenuric, Uloric, Febuxostat Viatris (previously Febuxostat Mylan), Febuxostat Krka
Drug Type
Small Molecule
Chemical Formula
C16H16N2O3S
CAS Number
144060-53-7
Unique Ingredient Identifier
101V0R1N2E
Background

Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate r...

Indication

Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricem...

Associated Conditions
Chronic, symptomatic Hyperuricemia
Associated Therapies
-
Clinical Trials
Related News

Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure

First Posted Date
2011-11-16
Last Posted Date
2019-12-16
Lead Sponsor
University of California, San Diego
Target Recruit Count
47
Registration Number
NCT01472692
Locations
🇺🇸

Univerisity Of California San Diego, San Diego, California, United States

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

First Posted Date
2011-08-15
Last Posted Date
2015-04-03
Lead Sponsor
CymaBay Therapeutics, Inc.
Target Recruit Count
27
Registration Number
NCT01416402

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

Not Applicable
Completed
Conditions
Diabetes
Chronic Kidney Disease
Interventions
Drug: Placebo
Drug: Febuxostat
First Posted Date
2011-05-09
Last Posted Date
2016-10-03
Lead Sponsor
University of Utah
Target Recruit Count
80
Registration Number
NCT01350388
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
Drug: Febuxostat
First Posted Date
2011-04-05
Last Posted Date
2015-09-17
Lead Sponsor
Paul N. Hopkins
Target Recruit Count
49
Registration Number
NCT01328769
Locations
🇺🇸

Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States

An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

First Posted Date
2010-04-29
Last Posted Date
2019-08-07
Lead Sponsor
University of South Florida
Target Recruit Count
74
Registration Number
NCT01112982
Locations
🇺🇸

University of South Florida Medical Clinics, Tampa, Florida, United States

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Phase 3
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: Febuxostat
Drug: Allopurinol
First Posted Date
2010-04-09
Last Posted Date
2018-06-14
Lead Sponsor
Takeda
Target Recruit Count
6198
Registration Number
NCT01101035

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

Phase 2
Completed
Conditions
Renal Impairment
Interventions
Drug: Placebo
Drug: Febuxostat
First Posted Date
2010-03-08
Last Posted Date
2013-09-25
Lead Sponsor
Takeda
Target Recruit Count
96
Registration Number
NCT01082640

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

Phase 2
Completed
Conditions
Joint Damage
Interventions
Drug: Placebo for Febuxostat
Drug: Febuxostat
First Posted Date
2010-03-02
Last Posted Date
2014-09-10
Lead Sponsor
Takeda
Target Recruit Count
314
Registration Number
NCT01078389

Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

First Posted Date
2010-03-01
Last Posted Date
2013-02-15
Lead Sponsor
Takeda
Target Recruit Count
99
Registration Number
NCT01077284

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

First Posted Date
2009-10-15
Last Posted Date
2011-01-06
Lead Sponsor
Nuon Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT00995618
Locations
🇺🇸

Nuon Investigative Site, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy